
Cullinan Therapeutics shows strong multi-asset pipeline with key drug milestones boosting funding prospects.
Cullinan Therapeutics offers a diversified portfolio with near-, mid-, and long-term value drivers, reducing dependence on external funding. Positive Phase 3 results for Zipalertinib and upcoming regulatory milestones could provide crucial funding to...


